Sandoz extends SYMJEPI (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine
[caption id="attachment_9277" align="aligncenter" width="747"]
Press Release[/caption]

- Adult and pediatric?doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1
- SYMJEPI will help address critical impact of ongoing epinephrine auto-injector shortages2for the one in 50 Americans at risk for anaphylaxis3
- Sandoz is committed to helping people access high quality healthcare at affordable prices, with strong focus on areas of unmet patient need